Why Be One Protein When You Can Affect Many? The Multiple Roles of YB-1 in Lung Cancer and Mesothelioma

Lung cancers and malignant pleural mesothelioma (MPM) have some of the worst 5-year survival rates of all cancer types, primarily due to a lack of effective treatment options for most patients. Targeted therapies have shown some promise in thoracic cancers, although efficacy is limited only to patients harboring specific mutations or target expression. Although a number of actionable mutations have now been identified, a large population of thoracic cancer patients have no therapeutic options outside of first-line chemotherapy. It is therefore crucial to identify alternative targets that might lead to the development of new ways of treating patients diagnosed with these diseases. The multifunctional oncoprotein Y-box binding protein-1 (YB-1) could serve as one such target. Recent studies also link this protein to many inherent behaviors of thoracic cancer cells such as proliferation, invasion, metastasis and involvement in cancer stem-like cells. Here, we review the regulation of YB-1 at the transcriptional, translational, post-translational and sub-cellular levels in thoracic cancer and discuss its potential use as a biomarker and therapeutic target.

[1]  V. Thirumala,et al.  Cancer stem cells: Road to therapeutic resistance and strategies to overcome resistance. , 2020, Biochimica et biophysica acta. Molecular basis of disease.

[2]  Chuong D. Hoang,et al.  MicroRNA-215-5p Treatment Suppresses Mesothelioma Progression via the MDM2-p53-Signaling Axis. , 2019, Molecular therapy : the journal of the American Society of Gene Therapy.

[3]  D. Kuang,et al.  Targeting the YB-1/PD-L1 Axis to Enhance Chemotherapy and Antitumor Immunity , 2019, Cancer Immunology Research.

[4]  P. Meldgaard,et al.  EGFR Gene Polymorphism Predicts Improved Outcome in Patients With EGFR Mutation-positive Non-small cell Lung Cancer Treated With Erlotinib. , 2019, Clinical lung cancer.

[5]  A. Aref,et al.  Exosomes: composition, biogenesis, and mechanisms in cancer metastasis and drug resistance , 2019, Molecular Cancer.

[6]  R. Weinberg,et al.  Acquisition of a hybrid E/M state is essential for tumorigenicity of basal breast cancer cells , 2019, Proceedings of the National Academy of Sciences.

[7]  A. Addeo,et al.  Next Generation Sequencing and Genetic Alterations in Squamous Cell Lung Carcinoma: Where Are We Today? , 2019, Front. Oncol..

[8]  Zhijian Zhang,et al.  MicroRNA-382 inhibits cancer cell growth and metastasis in NSCLC via targeting LMO3 , 2019, Experimental and therapeutic medicine.

[9]  A. Tsao,et al.  Use of Immune Checkpoint Inhibitors in Mesothelioma , 2019, Current Treatment Options in Oncology.

[10]  P. Black,et al.  The Oncolytic Adenovirus XVir-N-31 as a Novel Therapy in Muscle-Invasive Bladder Cancer. , 2019, Human gene therapy.

[11]  C. Sears DNA repair as an emerging target for COPD-lung cancer overlap. , 2019, Respiratory investigation.

[12]  Zhongjun Liu,et al.  Y‐box binding protein‐1 promotes tumorigenesis and progression via the epidermal growth factor receptor/AKT pathway in spinal chordoma , 2018, Cancer science.

[13]  C. Huang,et al.  LncRNA HULC promotes non-small cell lung cancer cell proliferation and inhibits the apoptosis by up-regulating sphingosine kinase 1 (SPHK1) and its downstream PI3K/Akt pathway. , 2018, European review for medical and pharmacological sciences.

[14]  R. Dighe,et al.  The soluble ligand Y box-1 activates Notch3 receptor by binding to epidermal growth factor like repeats 20-23. , 2018, Archives of biochemistry and biophysics.

[15]  Guiming Zhang,et al.  Sex Differences in the Association between Night Shift Work and the Risk of Cancers: A Meta-Analysis of 57 Articles , 2018, Disease markers.

[16]  Wenyuan Zhao,et al.  The long noncoding RNA LINC00312 induces lung adenocarcinoma migration and vasculogenic mimicry through directly binding YBX1 , 2018, Molecular Cancer.

[17]  Mi Young Lee,et al.  The Potential Roles of Extracellular Vesicles in Cigarette Smoke-Associated Diseases , 2018, Oxidative medicine and cellular longevity.

[18]  L. Philipsen,et al.  Cold shock Y-box binding protein-1 acetylation status in monocytes is associated with systemic inflammation and vascular damage. , 2018, Atherosclerosis.

[19]  S. Chiu,et al.  Fisetin targets YB-1/RSK axis independent of its effect on ERK signaling: insights from in vitro and in vivo melanoma models , 2018, Scientific Reports.

[20]  A. Pollice,et al.  Oxidative Stress Causes Enhanced Secretion of YB-1 Protein that Restrains Proliferation of Receiving Cells , 2018, Genes.

[21]  Yanqin Sun,et al.  miR-216a-5p inhibits malignant progression in small cell lung cancer: involvement of the Bcl-2 family proteins , 2018, Cancer management and research.

[22]  Toru Tanaka,et al.  Mechanism responsible for inhibitory effect of indirubin 3′‐oxime on anticancer agent‐induced YB‐1 nuclear translocation in HepG2 human hepatocellular carcinoma cells , 2018, Experimental cell research.

[23]  F. Hirsch,et al.  Scientific Advances and New Frontiers in Mesothelioma Therapeutics. , 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[24]  Myung-Chul Kim,et al.  Hypoxia promotes acquisition of aggressive phenotypes in human malignant mesothelioma , 2018, BMC Cancer.

[25]  D. Zips,et al.  Stress-Induced Phosphorylation of Nuclear YB-1 Depends on Nuclear Trafficking of p90 Ribosomal S6 Kinase , 2018, International journal of molecular sciences.

[26]  B. Yadav,et al.  Expression and network analysis of YBX1 interactors for identification of new drug targets in lung adenocarcinoma , 2018, Journal of genomics.

[27]  D. Beer,et al.  Silencing of Long Noncoding RNA MIR22HG Triggers Cell Survival/Death Signaling via Oncogenes YBX1, MET, and p21 in Lung Cancer. , 2018, Cancer research.

[28]  J. Testa,et al.  Inactivation of Tp53 and Pten drives rapid development of pleural and peritoneal malignant mesotheliomas , 2018, Journal of cellular physiology.

[29]  M. Wiese,et al.  Small‐molecule inhibitors of multidrug resistance‐associated protein 1 and related processes: A historic approach and recent advances , 2018, Medicinal research reviews.

[30]  D. Baines,et al.  Effective silencing of ENaC by siRNA delivered with epithelial-targeted nanocomplexes in human cystic fibrosis cells and in mouse lung , 2018, Thorax.

[31]  F. Meric-Bernstam,et al.  Targeting the PI3K pathway in cancer: are we making headway? , 2018, Nature Reviews Clinical Oncology.

[32]  N. Imamoto,et al.  Y-box protein-associated acidic protein (YBAP1/C1QBP) affects the localization and cytoplasmic functions of YB-1 , 2018, Scientific Reports.

[33]  T. Voet,et al.  Identification of the tumour transition states occurring during EMT , 2018, Nature.

[34]  Jia-bao Liu,et al.  LncRNA DANCR Promotes Lung Cancer by Sequestering miR-216a , 2018, Cancer control : journal of the Moffitt Cancer Center.

[35]  Jianbo Gao,et al.  TP53TG1 enhances cisplatin sensitivity of non-small cell lung cancer cells through regulating miR-18a/PTEN axis , 2018, Cell & Bioscience.

[36]  A. Shukla,et al.  Exosomes from asbestos‐exposed cells modulate gene expression in mesothelial cells , 2018, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[37]  M. Szołkowska,et al.  Malignant pleural mesothelioma: main topics of American Society of Clinical Oncology clinical practice guidelines for diagnosis and treatment. , 2018, Journal of thoracic disease.

[38]  R. Tsutsumi,et al.  YBX1 at the crossroads of non-coding transcriptome, exosomal, and cytoplasmic granular signaling. , 2018, European journal of cell biology.

[39]  Xiaoting Li,et al.  LncRNA GAS5 regulates ischemic stroke as a competing endogenous RNA for miR-137 to regulate the Notch1 signaling pathway. , 2018, Biochemical and biophysical research communications.

[40]  S. Gadgeel,et al.  Role of chemotherapy and targeted therapy in early-stage non-small cell lung cancer , 2018, Expert review of anticancer therapy.

[41]  Monika Haemmerle,et al.  From biomarkers to therapeutic targets—the promises and perils of long non-coding RNAs in cancer , 2017, Cancer and Metastasis Reviews.

[42]  Han Liu,et al.  A self-assembled polyjuglanin nanoparticle loaded with doxorubicin and anti-Kras siRNA for attenuating multidrug resistance in human lung cancer. , 2017, Biochemical and biophysical research communications.

[43]  Jifeng Feng,et al.  High YBX1 expression indicates poor prognosis and promotes cell migration and invasion in nasopharyngeal carcinoma , 2017, Experimental cell research.

[44]  C. Pirker,et al.  Dysregulated Expression of the MicroRNA miR‐137 and Its Target YBX1 Contribute to the Invasive Characteristics of Malignant Pleural Mesothelioma , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[45]  Qingqing Zhu,et al.  The biology, function and clinical implications of exosomes in lung cancer. , 2017, Cancer letters.

[46]  W. Schiemann,et al.  The WAVE3-YB1 interaction regulates cancer stem cells activity in breast cancer , 2017, Oncotarget.

[47]  A. Berns,et al.  Comprehensive Pharmacogenomic Profiling of Malignant Pleural Mesothelioma Identifies a Subgroup Sensitive to FGFR Inhibition , 2017, Clinical Cancer Research.

[48]  Xuenong Zhang,et al.  Multifunctional nanoparticles co‐delivering EZH2 siRNA and etoposide for synergistic therapy of orthotopic non‐small‐cell lung tumor , 2017, Journal of controlled release : official journal of the Controlled Release Society.

[49]  Fei Wang,et al.  YB‐1 expression promotes pancreatic cancer metastasis that is inhibited by microRNA‐216a , 2017, Experimental cell research.

[50]  R. Schekman,et al.  Broad role for YBX1 in defining the small noncoding RNA composition of exosomes , 2017, Proceedings of the National Academy of Sciences.

[51]  D. Bailey,et al.  Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study. , 2017, The Lancet. Oncology.

[52]  G. Matullo,et al.  Germline mutations in DNA repair genes predispose asbestos-exposed patients to malignant pleural mesothelioma. , 2017, Cancer letters.

[53]  G. Zalcman,et al.  A review of bevacizumab in the treatment of malignant pleural mesothelioma. , 2017, Future oncology.

[54]  D. Sivakumar,et al.  Identification of 2,4‐dihydroxy‐5‐pyrimidinyl imidothiocarbomate as a novel inhibitor to Y box binding protein‐1 (YB‐1) and its therapeutic actions against breast cancer , 2017, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[55]  A. Oronsky,et al.  What's New in SCLC? A Review , 2017, Neoplasia.

[56]  J. Hansen Night Shift Work and Risk of Breast Cancer , 2017, Current Environmental Health Reports.

[57]  J. Tamaru,et al.  Nuclear expression of Y box binding-1 is important for resistance to chemotherapy including gemcitabine in TP53-mutated bladder cancer. , 2017, International journal of oncology.

[58]  Hongyun Li,et al.  YBX1 promotes tumor growth by elevating glycolysis in human bladder cancer , 2017, Oncotarget.

[59]  J. Aerts,et al.  Novel insights into mesothelioma biology and implications for therapy , 2017, Nature Reviews Cancer.

[60]  R. Visconti,et al.  The between Now and Then of Lung Cancer Chemotherapy and Immunotherapy , 2017, International journal of molecular sciences.

[61]  Li Xu,et al.  Cisplatin induces expression of drug resistance-related genes through c-jun N-terminal kinase pathway in human lung cancer cells , 2017, Cancer Chemotherapy and Pharmacology.

[62]  Ruilian Li,et al.  Antimicrobial peptide LL-37 promotes the viability and invasion of skin squamous cell carcinoma by upregulating YB-1 , 2017, Experimental and therapeutic medicine.

[63]  F. Grossi,et al.  Exosomes: a new horizon in lung cancer. , 2017, Drug discovery today.

[64]  T. Guo,et al.  Transcriptional activation of NANOG by YBX1 promotes lung cancer stem-like properties and metastasis. , 2017, Biochemical and biophysical research communications.

[65]  Chengcheng Zhang,et al.  miR-137 inhibits the proliferation of human non-small cell lung cancer cells by targeting SRC3. , 2017, Oncology letters.

[66]  Y. Ung,et al.  Postoperative Adjuvant Systemic Therapy in Completely Resected Non–Small‐Cell Lung Cancer: A Systematic Review , 2017, Clinical lung cancer.

[67]  Nicolai J. Birkbak,et al.  Tracking the Evolution of Non‐Small‐Cell Lung Cancer , 2017, The New England journal of medicine.

[68]  M. Kris,et al.  Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I to IIIA Completely Resected Non-Small-Cell Lung Cancers: American Society of Clinical Oncology/Cancer Care Ontario Clinical Practice Guideline Update. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[69]  Ruowen Sun,et al.  Silencing of Y-box binding protein-1 by RNA interference inhibits proliferation, invasion, and metastasis, and enhances sensitivity to cisplatin through NF-κB signaling pathway in human neuroblastoma SH-SY5Y cells , 2017, Molecular and Cellular Biochemistry.

[70]  O. Lavrik,et al.  At the Interface of Three Nucleic Acids: The Role of RNA-Binding Proteins and Poly(ADP-ribose) in DNA Repair , 2017, Acta naturae.

[71]  A. Brenner,et al.  Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors , 2017, Investigational New Drugs.

[72]  Å. Borg,et al.  Clinical framework for next generation sequencing based analysis of treatment predictive mutations and multiplexed gene fusion detection in non-small cell lung cancer , 2017, Oncotarget.

[73]  B. Bay,et al.  YBX1 gene silencing inhibits migratory and invasive potential via CORO1C in breast cancer in vitro , 2017, BMC Cancer.

[74]  Jayantha Gunaratne,et al.  YBX1 gene silencing inhibits migratory and invasive potential via CORO1C in breast cancer in vitro , 2017, BMC Cancer.

[75]  J. Creaney,et al.  A Proteomic Analysis of the Malignant Mesothelioma Secretome Using iTRAQ. , 2017, Cancer genomics & proteomics.

[76]  Shuo Zhang,et al.  miR-382 inhibits tumor progression by targeting SETD8 in non-small cell lung cancer. , 2017, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[77]  I. Vendrell,et al.  Serum YB-1 (Y-box binding protein 1) as a biomarker of bone disease progression in patients with breast cancer and bone metastases , 2017, Journal of bone oncology.

[78]  Walter J Curran,et al.  Lung cancer: current therapies and new targeted treatments , 2017, The Lancet.

[79]  Jie Huang,et al.  Positive expression of Y-box binding protein 1 and prognosis in non-small cell lung cancer: a meta-analysis. , 2017, Oncotarget.

[80]  Yunlong Liu,et al.  Novel Serine 176 Phosphorylation of YBX1 Activates NF-κB in Colon Cancer* , 2017, The Journal of Biological Chemistry.

[81]  Jing Liu,et al.  Long noncoding RNA HULC modulates the phosphorylation of YB‐1 through serving as a scaffold of extracellular signal–regulated kinase and YB‐1 to enhance hepatocarcinogenesis , 2016, Hepatology.

[82]  D. Vallone,et al.  The tumor-associated YB-1 protein: new player in the circadian control of cell proliferation , 2016, Oncotarget.

[83]  R. Ni,et al.  Hyper-O-GlcNAcylation of YB-1 affects Ser102 phosphorylation and promotes cell proliferation in hepatocellular carcinoma. , 2016, Experimental cell research.

[84]  J. Jia,et al.  Antimicrobial peptide LL-37 promotes YB-1 expression, and the viability, migration and invasion of malignant melanoma cells , 2016, Molecular medicine reports.

[85]  A. Miyajima,et al.  Y-box binding protein-1 promotes hepatocellular carcinoma-initiating cell progression and tumorigenesis via Wnt/β-catenin pathway , 2016, Oncotarget.

[86]  O. Lavrik,et al.  Y-box-binding protein 1 as a non-canonical factor of base excision repair. , 2016, Biochimica et biophysica acta.

[87]  A. Sorokin,et al.  Transportin-1-dependent YB-1 nuclear import. , 2016, Biochemical and biophysical research communications.

[88]  F. Setién,et al.  Epigenetic inactivation of the p53-induced long noncoding RNA TP53 target 1 in human cancer , 2016, Proceedings of the National Academy of Sciences.

[89]  Toru Tanaka,et al.  Four nucleocytoplasmic-shuttling proteins and p53 interact specifically with the YB-NLS and are involved in anticancer reagent-induced nuclear localization of YB-1. , 2016, Biochemical and biophysical research communications.

[90]  T. Rauen,et al.  Cold shock protein YB-1 is involved in hypoxia-dependent gene transcription. , 2016, Biochemical and biophysical research communications.

[91]  R. Simpson,et al.  Secreted primary human malignant mesothelioma exosome signature reflects oncogenic cargo , 2016, Scientific Reports.

[92]  T. Jacks,et al.  Circadian Rhythm Disruption Promotes Lung Tumorigenesis. , 2016, Cell metabolism.

[93]  Dandan Zong,et al.  Notch signaling in lung diseases: focus on Notch1 and Notch3 , 2016, Therapeutic advances in respiratory disease.

[94]  W. Guo,et al.  YBX1 regulates tumor growth via CDC25a pathway in human lung adenocarcinoma , 2016, Oncotarget.

[95]  Guang-Biao Zhou,et al.  Long non-coding RNA stabilizes the Y-box-binding protein 1 and regulates the epidermal growth factor receptor to promote lung carcinogenesis , 2016, Oncotarget.

[96]  A. Stewart,et al.  Multiomic Analysis of the UV-Induced DNA Damage Response , 2016, Cell reports.

[97]  A. Pollice,et al.  ΔNp63α controls YB‐1 protein stability: evidence on YB‐1 as a new player in keratinocyte differentiation , 2016, Genes to cells : devoted to molecular & cellular mechanisms.

[98]  N. Nasreen,et al.  Nanoparticle-based targeted gene therapy for lung cancer. , 2016, American journal of cancer research.

[99]  Kazuhisa Takahashi,et al.  Oct4 plays a crucial role in the maintenance of gefitinib-resistant lung cancer stem cells. , 2016, Biochemical and biophysical research communications.

[100]  Zhendong Hu,et al.  Y-box-binding protein 1 promotes tumor progression and inhibits cisplatin chemosensitivity in esophageal squamous cell carcinoma. , 2016, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[101]  K. O'Byrne,et al.  Lung cancer stem cells: The root of resistance. , 2016, Cancer letters.

[102]  Thomas D. Wu,et al.  Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations , 2016, Nature Genetics.

[103]  S. Finn,et al.  Cancer stem cells in drug resistant lung cancer: Targeting cell surface markers and signaling pathways. , 2016, Pharmacology & therapeutics.

[104]  F. Mraiche,et al.  p90 ribosomal S6 kinase: a potential therapeutic target in lung cancer , 2016, Journal of Translational Medicine.

[105]  B. Wang,et al.  Overexpression of YB1 C‐terminal domain inhibits proliferation, angiogenesis and tumorigenicity in a SK‐BR‐3 breast cancer xenograft mouse model , 2016, FEBS open bio.

[106]  Abdel Kareem Azab,et al.  The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy , 2015, Hypoxia.

[107]  S. Maddika,et al.  HACE1 mediated K27 ubiquitin linkage leads to YB-1 protein secretion. , 2015, Cellular signalling.

[108]  P. Curmi,et al.  Poly(ADP-ribosyl)ation as a new posttranslational modification of YB-1. , 2015, Biochimie.

[109]  Ahmedin Jemal,et al.  Global trends of lung cancer mortality and smoking prevalence. , 2015, Translational lung cancer research.

[110]  S. Toyokuni,et al.  Malignant mesothelioma as an oxidative stress-induced cancer: An update. , 2015, Free radical biology & medicine.

[111]  Shuzhi Zang,et al.  MicroRNA-137 inhibits cell migration and invasion by targeting bone morphogenetic protein-7 (BMP7) in non-small cell lung cancer cells. , 2015, International journal of clinical and experimental pathology.

[112]  Yunlong Liu,et al.  Critical role of phosphorylation of serine 165 of YBX1 on the activation of NF-κB in colon cancer , 2015, Oncotarget.

[113]  Lijie He,et al.  Twist contributes to proliferation and epithelial-to-mesenchymal transition-induced fibrosis by regulating YB-1 in human peritoneal mesothelial cells. , 2015, The American journal of pathology.

[114]  Meng Li,et al.  Clinicopathological and prognostic significance of Twist overexpression in NSCLC , 2015, Oncotarget.

[115]  Yong-mei Song,et al.  A critical role for the long non‐coding RNA GAS5 in proliferation and apoptosis in non‐small‐cell lung cancer , 2015, Molecular carcinogenesis.

[116]  E. Izaurralde,et al.  Towards a molecular understanding of microRNA-mediated gene silencing , 2015, Nature Reviews Genetics.

[117]  S. Catalani,et al.  Reactive oxygen species a double-edged sword for mesothelioma , 2015, Oncotarget.

[118]  P. Ott,et al.  Pembrolizumab (MK-3475) in patients (pts) with extensive-stage small cell lung cancer (SCLC): Preliminary safety and efficacy results from KEYNOTE-028. , 2015 .

[119]  S. Dunn,et al.  Inhibition of RSK with the novel small-molecule inhibitor LJI308 overcomes chemoresistance by eliminating cancer stem cells , 2015, Oncotarget.

[120]  J. Zhao,et al.  lncRNA GAS5 enhances G1 cell cycle arrest via binding to YBX1 to regulate p21 expression in stomach cancer , 2015, Scientific Reports.

[121]  P. Sorensen,et al.  Translational Activation of HIF1α by YB-1 Promotes Sarcoma Metastasis. , 2015, Cancer cell.

[122]  R. Simpson,et al.  YBX1/YB-1 induces partial EMT and tumourigenicity through secretion of angiogenic factors into the extracellular microenvironment , 2015, Oncotarget.

[123]  Zhongyi Cheng,et al.  Suberoylanilide Hydroxamic Acid Treatment Reveals Crosstalks among Proteome, Ubiquitylome and Acetylome in Non-Small Cell Lung Cancer A549 Cell Line , 2015, Scientific Reports.

[124]  P. Sorensen,et al.  YB-1 regulates stress granule formation and tumor progression by translationally activating G3BP1 , 2015, The Journal of cell biology.

[125]  S. Kulp,et al.  A novel HIF-1α-integrin-linked kinase regulatory loop that facilitates hypoxia-induced HIF-1α expression and epithelial-mesenchymal transition in cancer cells , 2015, Oncotarget.

[126]  Jun Cui,et al.  YB-1 overexpression promotes a TGF-β1-induced epithelial-mesenchymal transition via Akt activation. , 2015, Biochemical and biophysical research communications.

[127]  C. Rudin,et al.  Small cell lung cancer: Where do we go from here? , 2015, Cancer.

[128]  I. Petruseva,et al.  Y-box binding protein 1 (YB-1) promotes detection of DNA bulky lesions by XPC-HR23B factor , 2015, Biochemistry (Moscow).

[129]  H. Checkoway,et al.  Night Shift Work and Lung Cancer Risk Among Female Textile Workers in Shanghai, China , 2015, Journal of occupational and environmental hygiene.

[130]  Shiladitya Sengupta,et al.  New paradigms in the repair of oxidative damage in human genome: mechanisms ensuring repair of mutagenic base lesions during replication and involvement of accessory proteins , 2015, Cellular and Molecular Life Sciences.

[131]  B. Shapiro,et al.  Triggering of RNA Interference with RNA–RNA, RNA–DNA, and DNA–RNA Nanoparticles , 2014, ACS nano.

[132]  Chirayu Pankaj Goswami,et al.  PROGgeneV2: enhancements on the existing database , 2014, BMC Cancer.

[133]  Leonid Peshkin,et al.  A Noncanonical Frizzled2 Pathway Regulates Epithelial-Mesenchymal Transition and Metastasis , 2014, Cell.

[134]  K. Syrigos,et al.  mTOR pathway: A current, up-to-date mini-review (Review) , 2014, Oncology letters.

[135]  B. Ghanim,et al.  Fibroblast growth factor receptor inhibition is active against mesothelioma and synergizes with radio- and chemotherapy. , 2014, American journal of respiratory and critical care medicine.

[136]  A. Schrader,et al.  Clinical significance of epithelial-mesenchymal transition , 2014, Clinical and Translational Medicine.

[137]  David C. Rice,et al.  Frequent Coamplification and Cooperation between C-MYC and PVT1 Oncogenes Promote Malignant Pleural Mesothelioma , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[138]  T. Uchiumi,et al.  Targeting ribosomal S6 kinases/Y‐box binding protein‐1 signaling improves cellular sensitivity to taxane in prostate cancer , 2014, The Prostate.

[139]  M. Kitagawa,et al.  YB‐1 promotes transcription of cyclin D1 in human non‐small‐cell lung cancers , 2014, Genes to cells : devoted to molecular & cellular mechanisms.

[140]  R. Stahel,et al.  GAS5 long non-coding RNA in malignant pleural mesothelioma , 2014, Molecular Cancer.

[141]  R. Lai,et al.  YB-1 regulates Sox2 to coordinately sustain stemness and tumorigenic properties in a phenotypically distinct subset of breast cancer cells , 2014, BMC Cancer.

[142]  J. Fletcher,et al.  Multipoint targeting of the PI3K/mTOR pathway in mesothelioma , 2014, British Journal of Cancer.

[143]  B. Han,et al.  Association of XPC Polymorphisms and Lung Cancer Risk: A Meta-Analysis , 2014, PloS one.

[144]  S. Chiu,et al.  YB-1 expression promotes epithelial-to-mesenchymal transition in prostate cancer that is inhibited by a small molecule fisetin , 2014, Oncotarget.

[145]  K. Jung,et al.  A molecular targeting against nuclear factor-κB, as a chemotherapeutic approach for human malignant mesothelioma , 2014, Cancer medicine.

[146]  H. Moch,et al.  PI3K/mTOR Signaling in Mesothelioma Patients Treated with Induction Chemotherapy Followed by Extrapleural Pneumonectomy , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[147]  Peixuan Guo,et al.  Stable RNA nanoparticles as potential new generation drugs for cancer therapy. , 2014, Advanced drug delivery reviews.

[148]  G. Semenza Oxygen sensing, hypoxia-inducible factors, and disease pathophysiology. , 2014, Annual review of pathology.

[149]  F. Tanaka,et al.  Clinical Significance of Epithelial-Mesenchymal Transition-Associated Markers in Malignant Pleural Mesothelioma , 2014, Oncology.

[150]  F. Tacke,et al.  High prevalence of Y-box protein-1/p18 fragment in plasma of patients with malignancies of different origin , 2014, BMC Cancer.

[151]  Jan Budczies,et al.  Online Survival Analysis Software to Assess the Prognostic Value of Biomarkers Using Transcriptomic Data in Non-Small-Cell Lung Cancer , 2013, PloS one.

[152]  E. Hopper-Borge,et al.  Drug Resistance Mechanisms in Non-Small Cell Lung Carcinoma , 2013, Journal of cancer research updates.

[153]  V. Evdokimova,et al.  The proteolytic YB-1 fragment interacts with DNA repair machinery and enhances survival during DNA damaging stress , 2013, Cell cycle.

[154]  Jie Huang,et al.  Role of focal adhesion kinase in regulating YB-1-mediated paclitaxel resistance in ovarian cancer. , 2013, Journal of the National Cancer Institute.

[155]  U. Naumann,et al.  YB-1 dependent oncolytic adenovirus efficiently inhibits tumor growth of glioma cancer stem like cells , 2013, Journal of Translational Medicine.

[156]  S. Dooley,et al.  Cold shock Y-box protein-1 proteolysis autoregulates its transcriptional activities , 2013, Cell Communication and Signaling.

[157]  K. Darwiche,et al.  Immunomodifiers in combination with conventional chemotherapy in small cell lung cancer: a Phase II, randomized study , 2013, Drug design, development and therapy.

[158]  T. Nakano,et al.  Serum HMGB1 as a prognostic marker for malignant pleural mesothelioma , 2013, BMC Cancer.

[159]  Benjamin E. Gross,et al.  Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.

[160]  K. Kuroiwa,et al.  YB-1 suppression induces STAT3 proteolysis and sensitizes renal cancer to interferon-α , 2013, Cancer Immunology, Immunotherapy.

[161]  R. Rosell,et al.  The role of SOX2 in small cell lung cancer, lung adenocarcinoma and squamous cell carcinoma of the lung. , 2013, Translational lung cancer research.

[162]  A. Rosenwald,et al.  The feed-forward loop between YB-1 and MYC is essential for multiple myeloma cell survival , 2013, Leukemia.

[163]  L. Ovchinnikov,et al.  YB-1 Synthesis Is Regulated by mTOR Signaling Pathway , 2012, PloS one.

[164]  Ping Liu,et al.  YB-1 immunization combined with regulatory T-cell depletion induces specific T-cell responses that protect against neuroblastoma in the early stage. , 2012, Acta biochimica et biophysica Sinica.

[165]  B. Bao,et al.  The biological kinship of hypoxia with CSC and EMT and their relationship with deregulated expression of miRNAs and tumor aggressiveness. , 2012, Biochimica et biophysica acta.

[166]  Robert Gentleman,et al.  Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer , 2012, Nature Genetics.

[167]  H. Izumi,et al.  Association of nuclear YB-1 localization with lung resistance-related protein and epidermal growth factor receptor expression in lung cancer. , 2012, Clinical lung cancer.

[168]  Sarah E Seton-Rogers,et al.  Therapeutics: siRNAs jump the hurdle , 2012, Nature Reviews Cancer.

[169]  T. Brabletz To differentiate or not — routes towards metastasis , 2012, Nature Reviews Cancer.

[170]  Benjamin E. Gross,et al.  The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.

[171]  H. Mukhtar,et al.  Dual inhibition of phosphatidylinositol 3‐kinase/Akt and mammalian target of rapamycin signaling in human nonsmall cell lung cancer cells by a dietary flavonoid fisetin , 2012, International journal of cancer.

[172]  A. Shelling,et al.  YB-1, the E2F pathway, and regulation of tumor cell growth. , 2012, Journal of the National Cancer Institute.

[173]  P. Lara,et al.  MVP and vaults: a role in the radiation response , 2011, Radiation oncology.

[174]  T. Uchiumi,et al.  Twist1 and Y‐box‐binding protein‐1 promote malignant potential in bladder cancer cells , 2011, BJU international.

[175]  P. Tan,et al.  Prognostic Association of YB-1 Expression in Breast Cancers: A Matter of Antibody , 2011, PloS one.

[176]  T. Cramer,et al.  Hypoxia-mediated drug resistance: novel insights on the functional interaction of HIFs and cell death pathways. , 2011, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[177]  J. Blenis,et al.  The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. , 2011, Trends in biochemical sciences.

[178]  B. Ghanim,et al.  Temsirolimus Inhibits Malignant Pleural Mesothelioma Growth In Vitro and In Vivo: Synergism with Chemotherapy , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[179]  P. Boor,et al.  Extracellular YB-1 Blockade in Experimental Nephritis Upregulates Notch-3 Receptor Expression and Signaling , 2011, Nephron Experimental Nephrology.

[180]  S. Chiou,et al.  Coexpression of Oct4 and Nanog enhances malignancy in lung adenocarcinoma by inducing cancer stem cell-like properties and epithelial-mesenchymal transdifferentiation. , 2010, Cancer research.

[181]  T. Betsuyaku,et al.  Cigarette smoke induces nucleic-acid oxidation in lung fibroblasts. , 2010, American journal of respiratory cell and molecular biology.

[182]  M. Gleave,et al.  Molecular Decoy to the Y-Box Binding Protein-1 Suppresses the Growth of Breast and Prostate Cancer Cells whilst Sparing Normal Cell Viability , 2010, PloS one.

[183]  Ken Yamamoto,et al.  P300/CBP‐associated factor regulates Y‐box binding protein‐1 expression and promotes cancer cell growth, cancer invasion and drug resistance , 2010, Cancer science.

[184]  H. Pass,et al.  Programmed necrosis induced by asbestos in human mesothelial cells causes high-mobility group box 1 protein release and resultant inflammation , 2010, Proceedings of the National Academy of Sciences.

[185]  M. Bushell,et al.  Upregulated c-myc expression in multiple myeloma by internal ribosome entry results from increased interactions with and expression of PTB-1 and YB-1 , 2010, Oncogene.

[186]  C. Eaves,et al.  Y-box binding protein-1 induces the expression of CD44 and CD49f leading to enhanced self-renewal, mammosphere growth, and drug resistance. , 2010, Cancer research.

[187]  A. Braithwaite,et al.  Genotoxic stress-induced nuclear localization of oncoprotein YB-1 in the absence of proteolytic processing , 2010, Oncogene.

[188]  Ping Chen,et al.  Expression of MRP1, BCRP, LRP and ERCC1 as prognostic factors in non-small cell lung cancer patients receiving postoperative cisplatin-based chemotherapy. , 2009, The International journal of biological markers.

[189]  R. Orentas,et al.  Discovery of YB-1 as a new immunological target in neuroblastoma by vaccination in the context of regulatory T cell blockade. , 2009, Acta biochimica et biophysica Sinica.

[190]  Ping Chen,et al.  Expression of MRP1, BCRP, LRP, and ERCC1 in advanced non-small-cell lung cancer: correlation with response to chemotherapy and survival. , 2009, Clinical lung cancer.

[191]  C. Tognon,et al.  Reduced proliferation and enhanced migration: Two sides of the same coin? Molecular mechanisms of metastatic progression by YB-1 , 2009, Cell cycle.

[192]  T. Gu,et al.  Phosphorylation of the SSBP2 and ABL proteins by the ZNF198‐FGFR1 fusion kinase seen in atypical myeloproliferative disorders as revealed by phosphopeptide‐specific MS , 2009, Proteomics.

[193]  S. Dooley,et al.  YB-1 Acts as a Ligand for Notch-3 Receptors and Modulates Receptor Activation* , 2009, The Journal of Biological Chemistry.

[194]  W. Lam,et al.  The transcriptional induction of PIK3CA in tumor cells is dependent on the oncoprotein Y-box binding protein-1 , 2009, Oncogene.

[195]  S. Dooley,et al.  Y-box protein-1 is actively secreted through a non-classical pathway and acts as an extracellular mitogen , 2009, EMBO reports.

[196]  T. Triche,et al.  Translational activation of snail1 and other developmentally regulated transcription factors by YB-1 promotes an epithelial-mesenchymal transition. , 2009, Cancer cell.

[197]  So Ri Kim,et al.  Impact of oxidative stress on lung diseases , 2009, Respirology.

[198]  J. Moolman-Smook,et al.  RBBP6 interacts with multifunctional protein YB-1 through its RING finger domain, leading to ubiquitination and proteosomal degradation of YB-1. , 2008, Journal of molecular biology.

[199]  Yong-Yeon Cho,et al.  Y-box binding protein-1 serine 102 is a downstream target of p90 ribosomal S6 kinase in basal-like breast cancer cells , 2008, Breast Cancer Research.

[200]  K. Kohno,et al.  Regulatory Role of Human AP-Endonuclease (APE1/Ref-1) in YB-1-Mediated Activation of the Multidrug Resistance Gene MDR1 , 2008, Molecular and Cellular Biology.

[201]  T. Mak,et al.  PTEN regulates p300-dependent hypoxia-inducible factor 1 transcriptional activity through Forkhead transcription factor 3a (FOXO3a) , 2008, Proceedings of the National Academy of Sciences.

[202]  F. Schmidt Meta-Analysis , 2008 .

[203]  T. Nielsen,et al.  Epidermal growth factor receptor (EGFR) is transcriptionally induced by the Y-box binding protein-1 (YB-1) and can be inhibited with Iressa in basal-like breast cancer, providing a potential target for therapy , 2007, Breast Cancer Research.

[204]  M. Clarke,et al.  Cancer stem cells and tumor metastasis: first steps into uncharted territory. , 2007, Cell stem cell.

[205]  C. Heeschen,et al.  Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. , 2007, Cell stem cell.

[206]  C. Garbe,et al.  The increased expression of Y box‐binding protein 1 in melanoma stimulates proliferation and tumor invasion, antagonizes apoptosis and enhances chemoresistance , 2007, International journal of cancer.

[207]  B. Gansbacher,et al.  Inhibition of the multidrug-resistant phenotype by targeting YB-1 with a conditionally oncolytic adenovirus: implications for combinatorial treatment regimen with chemotherapeutic agents. , 2006, Cancer research.

[208]  Shuhua Ma,et al.  Reduced Stability of Mitogen-activated Protein Kinase Kinase-2 mRNA and Phosphorylation of Poly(A)-binding Protein (PABP) in Cells Overexpressing PABP* , 2006, Journal of Biological Chemistry.

[209]  G. Ceresoli,et al.  EGFR overexpression in malignant pleural mesothelioma. An immunohistochemical and molecular study with clinico-pathological correlations. , 2006, Lung cancer.

[210]  V. Evdokimova,et al.  Proteasome‐mediated cleavage of the Y‐box‐binding protein 1 is linked to DNA‐damage stress response , 2005, The EMBO journal.

[211]  M. Ladanyi Implications of P16/CDKN2A deletion in pleural mesotheliomas. , 2005, Lung cancer.

[212]  E. Yorida,et al.  Akt phosphorylates the Y-box binding protein 1 at Ser102 located in the cold shock domain and affects the anchorage-independent growth of breast cancer cells , 2005, Oncogene.

[213]  P. Schlag,et al.  YB-1 facilitates basal and 5-fluorouracil-inducible expression of the human major vault protein (MVP) gene , 2005, Oncogene.

[214]  H. Clevers,et al.  Wnt signalling in stem cells and cancer , 2005, Nature.

[215]  L. Ovchinnikov,et al.  YB-1 Autoregulates Translation of Its Own mRNA at or prior to the Step of 40S Ribosomal Subunit Joining , 2005, Molecular and Cellular Biology.

[216]  D. Ma,et al.  Effect of lung resistance-related protein on the resistance to cisplatin in human ovarian cancer cell lines. , 2004, Oncology reports.

[217]  G. Tortora,et al.  The role of EGFR inhibitors in nonsmall cell lung cancer , 2004, Current opinion in oncology.

[218]  M. Lebel,et al.  YB-1 promotes strand separation in vitro of duplex DNA containing either mispaired bases or cisplatin modifications, exhibits endonucleolytic activities and binds several DNA repair proteins. , 2004, Nucleic acids research.

[219]  A. Tossavainen Global Use of Asbestos and the Incidence of Mesothelioma , 2004, International journal of occupational and environmental health.

[220]  C. Witt,et al.  Nuclear YB‐1 expression as a negative prognostic marker in nonsmall cell lung cancer , 2004, European Respiratory Journal.

[221]  Sunil Singhal,et al.  Gene expression profiling of malignant mesothelioma. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[222]  Claude Denham,et al.  Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[223]  L. Penalva,et al.  Poly(A)-binding Protein Positively Affects YB-1 mRNA Translation through Specific Interaction with YB-1 mRNA* , 2003, The Journal of Biological Chemistry.

[224]  Satoru Takahashi,et al.  Regulation of YB-1 gene expression by GATA transcription factors. , 2003, Biochemical and biophysical research communications.

[225]  K. Kohno,et al.  Increased nuclear localization of transcription factor YB-1 in acquired cisplatin-resistant ovarian cancer , 2002, Journal of Cancer Research and Clinical Oncology.

[226]  H. Uramoto,et al.  p73 Interacts with c-Myc to Regulate Y-box-binding Protein-1 Expression* , 2002, The Journal of Biological Chemistry.

[227]  M. Bittner,et al.  Wnt5a signaling directly affects cell motility and invasion of metastatic melanoma. , 2002, Cancer cell.

[228]  Y. Maehara,et al.  Nuclear expression of the Y-box binding protein, YB-1, as a novel marker of disease progression in non-small cell lung cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[229]  Y. Soini,et al.  The expression of P-glycoprotein and multidrug resistance proteins 1 and 2 (MRP1 and MRP2) in human malignant mesothelioma. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[230]  P. Schlag,et al.  Hyperthermia-induced Nuclear Translocation of Transcription Factor YB-1 Leads to Enhanced Expression of Multidrug Resistance-related ABC Transporters* , 2001, The Journal of Biological Chemistry.

[231]  S. Khuder,et al.  Effect of cigarette smoking on major histological types of lung cancer: a meta-analysis. , 2001, Lung cancer.

[232]  H. Takano,et al.  Transcription factor Y-box binding protein 1 binds preferentially to cisplatin-modified DNA and interacts with proliferating cell nuclear antigen. , 1999, Cancer research.

[233]  K. Kohno,et al.  Direct Involvement of the Y-box Binding Protein YB-1 in Genotoxic Stress-induced Activation of the Human Multidrug Resistance 1 Gene* , 1998, The Journal of Biological Chemistry.

[234]  K. Kohno,et al.  Nuclear translocation of the Y‐box binding protein by ultraviolet irradiation , 1997, FEBS letters.

[235]  K. Kohno,et al.  Structural and functional analysis of the human Y-box binding protein (YB-1) gene promoter. , 1996, Nucleic acids research.

[236]  K Botzenhart,et al.  Reactive Oxygen Species , 2014 .

[237]  I. Weinstein,et al.  Amplification and expression of the human cyclin D gene in esophageal cancer. , 1992, Cancer research.

[238]  A. Wolffe,et al.  The Y-box factors: a family of nucleic acid binding proteins conserved from Escherichia coli to man. , 1992, The New biologist.

[239]  H. Liu,et al.  Treatment of small cell lung cancer. , 1991, Chinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih.

[240]  D. K. Didier,et al.  Characterization of the cDNA encoding a protein binding to the major histocompatibility complex class II Y box. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[241]  R. Stahel,et al.  GAS 5 long non-coding RNA in malignant pleural mesothelioma , 2017 .

[242]  C. L. Ventola Cancer Immunotherapy, Part 3: Challenges and Future Trends. , 2017, P & T : a peer-reviewed journal for formulary management.

[243]  Self-Concept Variables Sex Differences in , 2016 .

[244]  G. Giaccone,et al.  Treatment of Small-Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American College of Chest Physicians Guideline. , 2016, Journal of oncology practice / American Society of Clinical Oncology.

[245]  K. Kerr,et al.  Survival from malignant mesothelioma: where are we now? , 2015, The journal of the Royal College of Physicians of Edinburgh.

[246]  W. Bi,et al.  miR-382 inhibits osteosarcoma metastasis and relapse by targeting Y box-binding protein 1. , 2015, Molecular therapy : the journal of the American Society of Gene Therapy.

[247]  B. Schittek,et al.  Y-box binding protein 1--a prognostic marker and target in tumour therapy. , 2014, European journal of cell biology.

[248]  L. Ovchinnikov,et al.  YB‐1 protein: functions and regulation , 2014, Wiley interdisciplinary reviews. RNA.

[249]  C. Print,et al.  YB-1: oncoprotein, prognostic marker and therapeutic target? , 2013, The Biochemical journal.

[250]  Yong Lin,et al.  NF-kappaB in lung cancer, a carcinogenesis mediator and a prevention and therapy target. , 2011, Frontiers in bioscience.

[251]  J. Rich,et al.  Hypoxia and hypoxia inducible factors in cancer stem cell maintenance. , 2010, Current topics in microbiology and immunology.

[252]  H. Izumi,et al.  Twist promotes tumor cell growth through YB-1 expression. , 2008, Cancer research.

[253]  M. Volm,et al.  Prognostic relevance of c-Myc and caspase-3 for patients with non-small cell lung cancer. , 2000, Oncology reports.

[254]  T. Chao,et al.  Combination chemoimmunotherapy with interferon-alpha and cisplatin in patients with advanced non-small cell lung cancer. , 1995, Zhonghua yi xue za zhi = Chinese medical journal; Free China ed.

[255]  A. Rusanov [Stomach cancer]. , 1974, Voprosy onkologii.

[256]  A Critical , 2022 .